Claims for Patent: 9,056,120

Summary for Patent: 9,056,120

Title:	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
Abstract:	Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administrations of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dione in combination with 5-azacytidine.
Inventor(s):	Zeldis; Jerome B. (Princeton, NJ)
Assignee:	Celgene Corporation (Summit, NJ)
Application Number:	13/801,262
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,056,120
Patent Claims:	1. A method of treating myelodysplastic syndrome, which comprises administering to a patient in need thereof about 1 mg to about 25 mg per day of a compound having the formula: ##STR00010## or a pharmaceutically acceptable salt, solvate or stereoisomer thereof. 2. The method of claim 1, wherein the myelodysplastic syndrome is refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or chronic myelomonocytic leukemia. 3. The method of claim 1, wherein the compound is ##STR00011## and is not a pharmaceutically acceptable salt, solvate or stereoisomer. 4. The method of claim 1, wherein the compound is a pharmaceutically acceptable salt. 5. The method of claim 1, wherein the compound is a pharmaceutically acceptable solvate. 6. The method of claim 1, wherein the compound is a pharmaceutically acceptable stereoisomer. 7. The method of claim 1, wherein the patient is not previously treated for a myelodysplastic syndrome. 8. The method of claim 1, wherein the patient has been previously treated for a myelodysplastic syndrome. 9. The method of claim 1, which further comprises administering a therapeutically effective amount of a second active agent. 10. The method of claim 9, wherein the second active agent is dexamethasone. 11. The method of claim 9, wherein the second active agent is azacitidine. 12. The method of claim 1, wherein the compound is administered before, during or after transplanting umbilical cord blood, placental blood, peripheral blood stem cell, hematopoietic stem cell preparation or bone marrow in the patient. 13. The method of claim 1, wherein the compound is administered cyclically. 14. The method of claim 1, wherein compound is administered for 21 consecutive days followed by seven consecutive days of rest in a 28 day cycle. 15. The method of claim 1, which comprises cyclically administering the compound until disease progression or unacceptable toxicity. 16. The method of claim 1, wherein the compound is administered in an amount of about 2.5 mg per day. 17. The method of claim 1, wherein the compound is administered in an amount of about 5 mg per day. 18. The method of claim 1, wherein the compound is administered in an amount of about 10 mg per day. 19. The method of claim 1, wherein the compound is administered in an amount of about 15 mg per day. 20. The method of claim 1, wherein the compound is administered in an amount of about 20 mg per day. 21. The method of claim 1, wherein the compound is administered in an amount of about 25 mg per day. 22. The method of claim 1, wherein the compound is administered in an amount from about 5 mg per day to about 25 mg per day for 21 consecutive days followed by seven consecutive days of rest in a 28 day cycle. 23. The method of claim 1, wherein the compound is administered in an amount of about 10 mg per day or about 15 mg per day for 21 consecutive days followed by seven consecutive days of rest in a 28 day cycle. 24. The method of claim 1, wherein the compound is administered orally. 25. The method of claim 24, wherein the compound is administered in the form of a capsule or tablet. 26. The method of claim 25, wherein the compound is administered in a capsule in an amount from about 1 mg to about 25 mg. 27. The method of claim 25, wherein the compound is administered in a capsule in an amount of about 2.5 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg or about 25 mg. 28. A method of treating transfusion dependent anemia due to low to intermediate-1-risk myelodysplastic syndrome, which comprises administering to a patient in need thereof about 1 mg to about 25 mg per day of a compound having the formula: ##STR00012## or a pharmaceutically acceptable salt, solvate or stereoisomer thereof. 29. The method of claim 28, wherein the compound is ##STR00013## and is not a pharmaceutically acceptable salt, solvate or stereoisomer. 30. The method of claim 28, wherein the compound is a pharmaceutically acceptable salt. 31. The method of claim 28, wherein the compound is a pharmaceutically acceptable solvate. 32. The method of claim 28, wherein the compound is a pharmaceutically acceptable stereoisomer. 33. The method of claim 28, wherein the patient is not previously treated for a myelodysplastic syndrome. 34. The method of claim 28, wherein the patient has been previously treated for a myelodysplastic syndrome. 35. The method of claim 28, which further comprises administering a therapeutically effective amount of a second active agent. 36. The method of claim 35, wherein the second active agent is dexamethasone. 37. The method of claim 35, wherein the second active agent is azacitidine. 38. The method of claim 28, wherein the compound is administered before, during or after transplanting umbilical cord blood, placental blood, peripheral blood stem cell, hematopoietic stem cell preparation or bone marrow in the patient. 39. The method of claim 28, wherein the compound is administered cyclically. 40. The method of claim 28, wherein compound is administered for 21 consecutive days followed by seven consecutive days of rest in a 28 day cycle. 41. The method of claim 28, which comprises cyclically administering the compound until disease progression or unacceptable toxicity. 42. The method of claim 28, wherein the compound is administered in an amount of about 2.5 mg per day. 43. The method of claim 28, wherein the compound is administered in an amount of about 5 mg per day. 44. The method of claim 28, wherein the compound is administered in an amount of about 10 mg per day. 45. The method of claim 28, wherein the compound is administered in an amount of about 15 mg per day. 46. The method of claim 28, wherein the compound is administered in an amount of about 20 mg per day. 47. The method of claim 28, wherein the compound is administered in an amount of about 25 mg per day. 48. The method of claim 28, wherein the compound is administered in an amount from about 5 mg per day to about 25 mg per day for 21 consecutive days followed by seven consecutive days of rest in a 28 day cycle. 49. The method of claim 28, wherein the compound is administered in an amount of about 10 mg per day or about 15 mg per day for 21 consecutive days followed by seven consecutive days of rest in a 28 day cycle. 50. The method of claim 28, wherein the compound is administered orally. 51. The method of claim 50, wherein the compound is administered in the form of a capsule or tablet. 52. The method of claim 51, wherein the compound is administered in a capsule in an amount from about 1 mg to about 25 mg. 53. The method of claim 51, wherein the compound is administered in a capsule in an amount of about 2.5 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg or about 25 mg.